Integrating biologic agents into management of moderate-to-severe psoriasis: A consensus of the Canadian Psoriasis Expert Panel

Journal of Cutaneous Medicine and Surgery

Volumn 8, Issue 5, 2004, Pages 321-337

  Guenther, Lyn ^a,b   Langley, Richard G ^c   Shear, Neil H ^d,e   Bissonnette, Robert ^f   Ho, Vincent ^g   Lynde, Charles ^h,i   Murray, Eileen ^j,k   Papp, Kim ^l   Poulin, Yves ^m,n   Zip, Catherine ^o,p  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Guenther Dermatology Research Centre   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Ventana Clinical Research Corporation   (Canada)

^f INNOVADERM RESEARCH   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h UNIVERSITY HEALTH NETWORK   (Canada)

ⁱ Lynde Centre for Dermatology Canada   (Canada)

^j UNIVERSITY OF MANITOBA   (Canada)

^k Winnipeg Clinic   (Canada)

^l PROBITY MEDICAL RESEARCH   (Canada)

^m UNIVERSITÉ LAVAL   (Canada)

ⁿ Centre Dermatologique   (Canada)

^o UNIVERSITY OF CALGARY   (Canada)

^p Dermatology Centre   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CALCIPOTRIOL; COAL TAR; CYCLOSPORIN; DITHRANOL; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID DERIVATIVE; INFLIXIMAB; METHOTREXATE; PSORALEN; SALICYLIC ACID; TAZAROTENE;

ACTINIC KERATOSIS; ALGORITHM; ARTICLE; BIOLOGICAL THERAPY; BONE MARROW TOXICITY; CHILL; CLIMATOTHERAPY; CLINICAL TRIAL; CONSENSUS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG MECHANISM; EDUCATION; ELASTICITY; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERTENSION; INCIDENCE; INFECTION; INJURY; KIDNEY DISEASE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; MEDICAL EXPERT; MYALGIA; NAUSEA; PATIENT SATISFACTION; PHARYNGITIS; PHOTOAGING; PHOTOTHERAPY; PHOTOTOXICITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PUVA; QUALITY OF LIFE; RHINITIS; SINUSITIS; SKIN PIGMENTATION; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; ULTRAVIOLET B RADIATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WRINKLE; XEROSIS;

EID: 27544470540     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-005-0035-1     Document Type: Article

References (85)

1. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26:314-320.
2. Nail L, Gulliver W, Charmley P, et al. Search for the psoriasis susceptibility gene: the Newfoundland Study. Cutis 1999; 64:323-329.
3. Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther 2000; 25:1-10.
4. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003; 49:S57-S61.
5. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137:280-284.
6. Lebwohl M, Menter A, Koo J, et al. Psoriasis: Treatment options and patient management Ed. Portland, OR: National Psoriasis Foundation, 2002, pp 30-31 Physician Patient guide The algorithm cited is available @ http://www.psoriasis.org/files/pdfs/press/algorithm.pdf.
7. Travis L, Weinberg JM. Medical backgrounder: psoriasis. Drugs Today (Barc) 2002; 38:847-865.
8. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014-2022.
9. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47:821-833.
10. Gottlieb AB, Chaudhari U, Mulcahy LD, et al. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003; 48:829-835.
11. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357:1842-1847.
12. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349:2004-2013.
13. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290:3073-3080.
14. Ortonne JP. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2003; 17(Suppl 2):12-16.
15. Tan MH, Lebwohl M. Psoriasis. Drugs Today (Barc) 1998; 34:641-647.
16. Brandrup F, Green A. The prevalence of psoriasis in Denmark. Acta Derm Venereol 1981; 61:344-346.
17. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13:450-456.
18. Whittam LR, McGibbon DH. The management of psoriasis. Int J Clin Pract 1998; 52:487-491.
19. Callen JP, Krueger GG, Lebwohl M, et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003; 49:897-899.
20. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?. J Am Acad Dermatol 2000; 43:281-285.
21. Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog Treat 2004; 15:27-29.
22. National Psoriasis Foundation. Facts: Psoriasis. http://www.psoriasis. org/facts/psoriasis/.2004.
23. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45:487-498quiz 499-502.
24. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001; 45:649-661quiz 662-664.
25. Gower WR Jr. Mechanism of glucocorticoid action. J Fla Med Assoc 1993; 80:697-700.
26. Foster RH, Broaden RN, Benfield P. Tazarotene. Drugs 1998; 55:705-711discussion 712.
27. Muller K. Current status and recent developments in anthracenone antipsoriatics. Curr Pharm Des 2000; 6:901-918.
28. Pardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: an algorithm-based approach for primary care physicians. Am Fam Physician 2000; 61:725-733, 736.
29. Camisa C, ed. UVB phototherapy and coal tar. In: Chapter 12, Camisa, C (ed.), Psoriasis, Boston, Blackwell Scientific, 1994, pp 205-226.
30. Gawkrodger Don behalf of the Therapy Guidelines and Audit Subcommittee of the British Association of DermatologistsCurrent management of psoriasis. J Dermatology Treat 1997; 8:27-55.
31. Krutmann J. Therapeutic photoimmunology: photoimmunological mechanisms in photo(chemo)therapy. J Photochem Photobiol B 1998; 44:159-164.
32. Melski JW, Tanenbaum L, Parrish JA, et al. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol 1977; 68:328-335.
33. Griffiths CE, Clark CM, Chalmers RJ, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4:1-125.
34. Gordon PM, Diffey BL, Matthews JN, et al. A randomized comparison of narrowband TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999; 41:728-732.
35. Honigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol 2001; 26:343-350.
36. Koo J, Lee E, Lee CS, et al. Psoriasis. J Am Acad Dermatol 2004; 50:613-622.
37. Ramsay CA, Schwartz BE, Lowson D, et al. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology 2000; 200:17-24.
38. Margolis D, Bilker W, Hennessy S, et al. The risk of malignancy associated with psoriasis. Arch Dermatol 2001; 137:778-789.
39. Compendium of pharmaceuticals and specialties. Ed. Ottawa: Canadian Pharmacists' Associatin, 2004.
40. Roenigk HH Jr, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38:478-485.
41. Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349:658-665.
42. Callis KP, Chadha A, Vaishnaw AK, et al. Reduction of CD45RP+ Effector T lymphocytes is not observed in the treatment of psoriasis with methotrexate. Presented at 63rd Annual Meeting of the Society for Investigative Dermatology Los Angeles, CA, poster abstract 220. May 15-18, 2002.
43. Ho VC, Griffiths CE, Berth-Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001; 44:643-651.
44. Shupack J, Abel E, Bauer E, et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol 1997; 36:423-432.
45. Roenigk HH Jr. Acitretih combination therapy. J Am Acad Dermatol 1999;41:S18-S21.
46. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139:719-727.
47. Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med 1999; 107:595-605.
48. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41:51-59.
49. Boerbooms AM, Kerstens PJ, Loenhout JWvan, et al. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995; 24:411-421.
50. Lebwohl M, Menter A, Koo J, et al. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 2004; 50:416-430.
51. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28:454-459.
52. Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol 1999; 41:S25-S28.
53. Kerkhof PCvan de. The management of psoriasis. Neth J Med 1998; 52:40-45.
54. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41:401-407.
55. Naldi L, Svensson A, Diepgen T, et al. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol 2003; 120:738-741.
56. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46:1-23quiz 26.
57. Gordon K, Pariser D, Langley R, et al. Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: Pooled results from randomized phase III trials. Presented at 62nd Annual Meeting of the American Acadamy of Dermatology, 6-11 February 2004, Washington, DC, poster 4.
58. Leonardi CI, Goffe B, Sobell J, et al. The safety of efalizumab in patients with moderate to severe plaque psoriasis: Summary of clinical trial experience. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6-11 February 2004, Washington, DC, poster 613.
59. Remicade® (infliximab), US prescribing information, 2003. Manufactured by Centocor, Inc.
60. Raptiva® (efalizumab), US prescribing information, 2004, http:// www.raptiva.com Manufactured by Genentech, Inc.
61. Enbrel® (etanercept), US prescribing information, 2004, http:// www.enbrel.comManufactured by Biogen, Idee, Inc.
62. Amevieve® (alefacept), US prescribing information, 2004, http://www.amevive.comgive manufacturer.
63. Cather JC, Abramovits W. Investigational therapies for psoriasis. J Am Acad Dermatol 2003; 49:S133-S138.
64. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002; 138:657-663.
65. Gordon KB, McCormick TS. Evolution of biologic therapies for the treatment of psoriasis. Skinmed 2003; 2:286-294.
66. Gottlieb AB, Evans R, Li S, et al. The efficacy of infliximab across a variety of subgroups with plaque psoriasis. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6-11 February 2004, Washington, DC, poster 615.
67. Gordon KB, Vaishnaw AK, O'Gorman J, et al. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003; 139:1563-1570.
68. Menter A, Gather JC. Long-term use of intravenous alefacept: Safety and off-treatment responses in patients who have received four or more courses of therapy. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6-11 February 2004, Washington, DC, poster 588.
69. Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol 2003; 4:131-139.
70. Gottlieb AB, Gordon KB, Caro I, et al. Long-term efalizumab therapy safely maintains psoriasis area and severity index improvement: Preliminary results from an open-label trial. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6-11 February 2004, Washington, DC, poster 611.
71. Menter A, Toth D, Glazer S, et al. Efficacy and safety of 24-week continuous efalizumab therapy in patients with moderate to severe plaque psoriasis. Presented at Summer Academy 2003 of the American Academy of Dermatology, 25-29 July 2003, Chicago, IL, poster 44.
72. Menter A, Hamilton T, Caro I, et al. Impact of efalizumab on patient-reported outcomes in patients with chronic moderate to severe plaque psoriasis: pooled results from three randomized phase III trials. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6-11 February 2004, Washington, DC, poster 608.
73. Stone S, Papp KA, Caro I, et al. Interpretation of positive patient response to efalizumab for the treatment of moderate to severe plaque psoriasis. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6-11 February 2004, Washington, DC, poster 610.
74. Leonardi CL, Elewski B, Camisa C, et al. The efficacy and safety of etanercept in the re-treatment of psoriasis after relapse. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6-11 February 2004, Washington, DC, poster 568.
75. Krueger GG, Lebwohl M, Wang A, et al. Continuance on etanercept after early incomplete response in patients with psoriasis. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6-11 February 2004, Washington, DC, poster 546.
76. Elewski BE, Boh E, Papp K, et al. Efficacy and safety of etanercept in patients with psoriasis: Results of a global phase III study. Presented at 62nd Annual Meeting of the American Academy of Dermatology, 6-11 February 2004, Washington, DC, poster 618.
77. Ogilvie A, Antoni C, Kavanaugh A, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): Substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy. Presented at 96th International Psoriasis Symposium, 18-22 June 2003, New York, NY, poster 8.
78. Feldman SR, Bala M, Menter A, et al. The quality of life of patients with severe psoriasis treated with infliximab. Presented at 62nd Annual Meeting of the American Academy of Dermatology, February 6-11 2004, Washington, DC, poster 7.
79. Guidelines of care for psoriasis. Committee on Guidelines of Care. Task Force on Psoriasis. J Am Acad Dermatol 1993; 28:632-637.
80. Lebwohl M. Combining the new biologic agents with our current psoriasis armamentarium. J Am Acad Dermatol 2003; 49:S118-S124.
81. Kostovic K, Nola I. Phototherapy (UVB) and photochemotherapy (PUVA) for psoriasis. Acta Clin Croat 2002; 41:103-112.
82. 8-Mop® capsules (methoxsalen capsules, USP, 10 mg), US prescribing information, 2003 ICN Pharmaceutical Inc.
83. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46:3151-3158.
84. The Lenercept Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized placebo-controlled multicenter study. Neurology 1999; 53:457-465.
85. Klareskog L, Heijde Dvan der, Jager JPde, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363:675-681.